EP3723509A1 - Complément alimentaire - Google Patents

Complément alimentaire

Info

Publication number
EP3723509A1
EP3723509A1 EP18830955.3A EP18830955A EP3723509A1 EP 3723509 A1 EP3723509 A1 EP 3723509A1 EP 18830955 A EP18830955 A EP 18830955A EP 3723509 A1 EP3723509 A1 EP 3723509A1
Authority
EP
European Patent Office
Prior art keywords
leaves
fruit
roots
moringa
seeds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP18830955.3A
Other languages
German (de)
English (en)
Inventor
Stefano Sala
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of EP3723509A1 publication Critical patent/EP3723509A1/fr
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/30—Dietetic or nutritional methods, e.g. for losing weight
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/105—Plant extracts, their artificial duplicates or their derivatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/06—Fungi, e.g. yeasts
    • A61K36/07—Basidiomycota, e.g. Cryptococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/41—Crassulaceae (Stonecrop family)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
    • A61K36/482—Cassia, e.g. golden shower tree
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/577—Malvaceae (Mallow family)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/577—Malvaceae (Mallow family)
    • A61K36/5775—Hibiscus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/63—Oleaceae (Olive family), e.g. jasmine, lilac or ash tree
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/70—Polygonaceae (Buckwheat family), e.g. spineflower or dock
    • A61K36/708—Rheum (rhubarb)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/74—Rubiaceae (Madder family)
    • A61K36/742—Coffea, e.g. coffee
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/88—Liliopsida (monocotyledons)
    • A61K36/899—Poaceae or Gramineae (Grass family), e.g. bamboo, corn or sugar cane

Definitions

  • the present invention relates to dietary supplement which is a composition comprising natural substances selected from the group which comprises: Olive (Olea europaea L.) leaves, Hibiscus (Hibiscus sabdariffa 1.) flowers, Garcinia gummi-gutta ( Garcinia cambogia) fruit, Red rice ( Oryza sativa L.) fermented seeds of Monascus Purpureus, Chinese rhubarb (Rheum palmatum L.
  • composition has been shown to have a surprising activity as a coadjuvant in slimming diets as well as to be surprisingly effective in counteracting characteristic metabolic syndrome symptoms .
  • compositions which promote weight loss have been described in the prior art.
  • US2005/276869 describes a dietary supplement for the treatment of obesity which comprises flowers of Cassia noname and citric acid.
  • US2006/222682 describes a nutraceutical drink for weight loss which comprises Moringa.
  • W02015/099616 describes a mixture to reduce muscle mass which comprises Rhodiola roots and green coffee extract.
  • Figure 2 Circumference measurements, a) Waist circumference is measured just above the right and left iliac crest, b) Hip circumference is measured in the maximum protrusion area, c) Thigh circumference is measured in the maximum protrusion area.
  • Figure 3 The charts show the effect of the product on weight (raw data on the left and variations with respect to To on the right) . Data are expressed as average ⁇ SE . * p ⁇ 0.05, ** p ⁇ 0.01, *** p ⁇ 0.001.
  • Figure 4 The charts show the effect of the product on abdomen circumference (raw data on the left and variations with respect to To on the right) . Data are expressed as average ⁇ SE . * p ⁇ 0.05, ** p ⁇ 0.01, *** p ⁇ 0.001.
  • Figure 5 The charts show the effect of the product on thigh circumference (raw data on the left and variations with respect to To on the right) . Data are expressed as average ⁇ SE . * p ⁇ 0.05, ** p ⁇ 0.01, *** p ⁇ 0.001.
  • Figure 6 The charts show the effect of the product on subcutaneous adipose tissue, abdomen (raw data on the left and variations with respect to To on the right) . Data are expressed as average ⁇ SE . * p ⁇ 0.05, ** p ⁇ 0.01, *** p ⁇ 0.001.
  • Figure 7 The charts show the effect of the product on subcutaneous adipose tissue, thigh (raw data on the left and variations with respect to To on the right) . Data are expressed as average ⁇ SE . * p ⁇ 0.05, ** p ⁇ 0.01, *** p ⁇ 0.001.
  • Figure 8 The charts show the effect of the product on subcutaneous adipose tissue, hips (raw data on the left and variations with respect to To on the right) . Data are expressed as average ⁇ SE . * p ⁇ 0.05, ** p ⁇ 0.01, *** p ⁇ 0.001.
  • Figure 9 The charts show the effect of the product on deep adipose tissue, abdomen (raw data on the left and variations with respect to To on the right) . Data are expressed as average ⁇ SE . * p ⁇ 0.05, ** p ⁇ 0.01, *** p ⁇ 0.001.
  • Figure 10 The charts show the effect of the product on deep adipose tissue, thigh (raw data on the left and variations with respect to To on the right) . Data are expressed as average ⁇ SE . * p ⁇ 0.05, ** p ⁇ 0.01, *** p ⁇ 0.001.
  • Figure 11 The charts show the effect of the product on deep adipose tissue, hips (raw data on the left and variations with respect to To on the right) . Data are expressed as average ⁇ SE . * p ⁇ 0.05, ** p ⁇ 0.01, *** p ⁇ 0.001.
  • Figure 12 The charts show the effect of the product on glycaemia levels (raw data on the left and variations with respect to To on the right) . Data are expressed as average ⁇ SE . * p ⁇ 0.05, ** p
  • Figure 13 The charts show the effect of the product on cholesterol levels (raw data on the left and variations with respect to To on the right) . Data are expressed as average ⁇ SE . * p ⁇ 0.05, ** p ⁇ 0.01, *** p ⁇ 0.001.
  • Figure 14 The charts show the effect of the product on uric acid levels (raw data on the left and variations with respect to To on the right) . Data are expressed as average ⁇ SE . * p ⁇ 0.05, ** p
  • Figure 15 The charts show the effect of the product on systolic blood pressure (raw data on the left and variations with respect to To on the right) . Data are expressed as average ⁇ SE . * p ⁇ 0.05,
  • Figure 16 The charts show the effect of the product on diastolic blood pressure (raw data on the left and variations with respect to To on the right) . Data are expressed as average ⁇ SE . * p ⁇ 0.05,
  • Figure 17 The charts show the effect of the product on total body water (raw data on the left and variations with respect to To on the right) . Data are expressed as average ⁇ SE . * p ⁇ 0.05, ** p
  • Figure 18 The charts show the effect of the product on extracellular water (raw data on the left and variations with respect to To on the right) . Data are expressed as average ⁇ SE . * p ⁇ 0.05, ** p ⁇ 0.01, *** p ⁇ 0.001.
  • Said composition comprises natural substances selected from the group which comprises: leaves of Olive (Olea europaea L.), Hibiscus (Hibiscus sabdariffa 1.) flowers, Garcinia gummi-gutta ( Garcinia cambogia) fruit, Red rice ( Oryza sativa b.) fermented seeds of Monascus Purpureus, Chinese rhubarb (Rheum palmatum L.) roots, Cola ( Cola acuminata Schott) fruit, Moringa (Moringa oleifera Lamk.) seeds, Moringa (Moringa oleifera Lamk.) leaves, Nopal ( Opuntia ficus indica Mill.) cladodi, Cassia nomame ( Cassia mimosides L.
  • Table A shows botanical names as they are used in the present invention, the nomenclature of the BELFRIT list and the nomenclature of the list of the Italian Ministry of Health in Annex 1 of Ministerial Decree 9 July 2012. Unless otherwise indicated, it is understood that the nomenclature corresponds to the one used in the present description.
  • said composition further comprises one or more of the compounds selected from the group which consists of: magnesium lactate, dextrins, marine collagen, zinc gluconate, chromium picolinate.
  • suitable excipients are cellulose preparations such as maize starch, wheat starch, rice starch, potato starch, gelatin, tragacanth, methylcellulose, hydroxypropyl methylcellulose, sodium carboxymethyl cellulose, and/or polyvinylpyrrolidone (PVP) ; and various flavoring agents known in the art .
  • cellulose preparations such as maize starch, wheat starch, rice starch, potato starch, gelatin, tragacanth, methylcellulose, hydroxypropyl methylcellulose, sodium carboxymethyl cellulose, and/or polyvinylpyrrolidone (PVP) ; and various flavoring agents known in the art .
  • PVP polyvinylpyrrolidone
  • acidifying agents are added, preferably organic acids, such as citric acid, acetic acid, malic acid, tartaric acid, fumaric acid, succinic acid.
  • said composition comprises thickening agents selected from the group which comprises modified starches, such as oxidized starch, monostarch phosphate, distarch phosphate, phosphated distarch phosphate, acetylated distarch phosphate, acetylated starch, acetylated distarch adipate, hydroxypropylated starch, hydroxypropylated distarch phosphate, octenyl succinate of starch and sodium, pectins, alginic acid and alginates, agar-agar, carrageenan, locust bean gum, guar gum, tragacanth, xanthan gum, karaya gum, tara gum, gellan gum, cellulose.
  • modified starches such as oxidized starch, monostarch phosphate, distarch phosphate, phosphated distarch phosphate, acetylated distarch phosphate, acetylated starch, acetyl
  • said composition comprises sweeteners selected from the group which comprises aspartame, acesulfame, saccharin, cyclamate and sucralose.
  • said composition comprises preservatives selected from the group which comprises sorbates, e.g. sorbic acid, potassium sorbate, benzoates, for example benzoic acid, sodium benzoate, phenyls and formates, nitrites and nitrates, acetates, lactates, propionates.
  • sorbates e.g. sorbic acid, potassium sorbate, benzoates, for example benzoic acid, sodium benzoate, phenyls and formates, nitrites and nitrates, acetates, lactates, propionates.
  • said composition comprises: leaves of Olive, Hibiscus (Hibiscus sabdariffa 1.) flowers, Garcinia gummi-gutta ( Garcinia cambogia) fruit, Red rice ( Oryza sativa h.) fermented seeds of Monascus Purpureus, Chinese rhubarb (Rheum palmatum L.) roots, Cola ( Cola acuminata Schott) fruit, Moringa (Moringa oleifera Lamk.) seeds, Moringa (Moringa oleifera Lamk.) leaves, Nopal ( Opuntia ficus indica Mill.) cladodi, Cassia nomame ( Cassia mimosides L. var.
  • Nomame makino leaves and fruit, Gugul ( Commiphora mukul Hook) resin, Coleus ( Plectranthus barbatus Andrews (Syn. Coleus Forskohlii) ) roots, Green coffee ( Coffea arabica L.) seeds, Common hawthorn ( Crataegus oxycantha L.) leaves, Caigua ( Cyclantera pedata Schard.) juice of the dehydrated fruit, Shitake ( Lentinula edodes (Berk.) Pegler) sporophores, Orthosiphon ( Orthosiphon stamineus Benth) leaves, Golden root (Rhodiola rosea L.) roots, Siberian ginseng (Eleutherococcus senticosus (Rupr.
  • said composition further comprises one or more acidifying agents, preferably citric acid, one or more thickeners, preferably xanthan gum, one or more sweeteners, preferably sucralose, one or more preservatives, preferably sodium benzoate and/or potassium sorbate.
  • acidifying agents preferably citric acid
  • thickeners preferably xanthan gum
  • sweeteners preferably sucralose
  • preservatives preferably sodium benzoate and/or potassium sorbate.
  • said composition comprises:
  • Garcinia gummi-gutta Garcinia cambogia fruit, Red rice ( Oryza sativa L.) fermented seeds of Monascus Purpureus, Chinese rhubarb (Rheum palmatum L.) roots, Cola ( Cola acuminata Schott) fruit, Moringa (Moringa oleifera Lamk.) seeds, Moringa (Moringa oleifera Lamk.) leaves, Nopal (Opuntia ficus indica Mill.) cladodi, Cassia nomame ( Cassia mimosides L. var.
  • Nomame makino leaves and fruit, Gugul ( Commiphora mukul Hook) resin, Coleus ( Plectranthus harhatus Andrews (Syn. Coleus Forskohlii) ) roots, Green coffee ( Coffea arabica L.) seeds, Common hawthorn ( Crataegus oxycantha L.) leaves, Caigua ( Cyclantera pedata Schard.) juice of the dehydrated fruit, Shitake ( Lentinula edodes (Berk.) Pegler) sporophores, Orthosiphon ( Orthosiphon stamineus Benth) leaves, Golden root (Rhodiola rosea L.) roots, Siberian ginseng (Eleutherococcus senticosus (Rupr.
  • said composition comprises (%w/V) : Olive ( Olea europaea L.) leaves between 1 and 3, Hibiscus (Hibiscus sabdariffa 1.) flowers between 0.5 and 3, Garcinia gummi-gutta ( Garcinia cambogia) fruit between 0.5 and 3, Red rice ( Oryza sativa L.) fermented seeds of Monascus Purpureus between 0.3 and 2, Chinese rhubarb (Rheum palmatum L.) roots between 0.2 and 1.5, Cola ( Cola acuminata Schott) fruit between 0.1 and 1, Moringa (Moringa oleifera Lamk.) seeds between 0.01 and 0.5, Moringa (Moringa oleifera Lamk.) leaves between 0.01 and 0.5, Nopal (Opuntia ficus indica Mill.) cladodi between 0 and 0.005, Cassia nomame (Cassia mimosides L.
  • said composition comprises (%w/V) : Olive ⁇ Olea europaea L.) leaves between 1 and 3, Hibiscus (Hibiscus sabdariffa 1.) flowers between 0.5 and 3, Garcinia gummi-gutta ⁇ Garcinia cambogia) fruit between 0.5 and 3, Red rice ( Oryza sativa L.) fermented seeds of Monascus Purpureus between 0.3 and 2, Chinese rhubarb (Rheum palmatum L.) roots between 0.2 and 1.5, Cola ( Cola acuminata Schott) fruit between 0.1 and 1, Moringa (Moringa oleifera Lamk.) seeds between 0.01 and 0.5, Moringa (Moringa oleifera Lamk.) leaves between 0.01 and 0.5, Nopal ( Opuntia ficus indica Mill.) cladodi between 0.001 and 0.005, Cassia nomame
  • Coleus Forskohlii ) roots between 0.001 and 0.005, Green coffee ( Coffea arabica L.) seeds between 0.001 and 0.005, Common hawthorn (Crataegus oxycantha L.) leaves between 0.001 and 0.005, Caigua ( Cyclantera pedata Schard.) juice of the dehydrated fruit between 0.001 and 0.005, Shitake ( Lentinula edodes ⁇ Berk.) Pegler) sporophores between 0.001 and 0.005, Orthosiphon ( Orthosiphon stamineus Benth) leaves between 0.001 and 0.005, Golden root (Rhodiola rosea L.) roots between 0.001 and 0.005, Siberian ginseng (Eleutherococcus senticosus (Rupr.
  • said composition comprises (%w/V) : Olive ⁇ Olea europaea L.) leaves 1.62, Hibiscus (Hibiscus sabdariffa 1.) flowers 1.35, Garcinia gummi-gutta ⁇ Garcinia cambogia) fruit 1.08, Red rice ( Oryza sativa L.) fermented seeds of Monascus Purpureus 0.902, Chinese rhubarb (Rheum palmatum L.) roots 0.54, Cola ( Cola acuminata Schott) fruit 0.270, Moringa (Moringa oleifera Lamk.) seeds 0.0675, Moringa (Moringa oleifera
  • Lamk. leaves 0.0675, Nopal ( Opuntia ficus indica Mill.) cladodi 0.0027, Cassia nomame ( Cassia mimosides L. var. Nomame makino) leaves and fruit 0.0027, Gugul ( Commiphora mukul Hook) resin 0.0027, Coleus ( Plectranthus barbatus andrews (Syn. Coleus
  • said composition consists in (%w/V) : Olive ⁇ Olea europaea L.) leaves 1.62, Hibiscus (Hibiscus sabdariffa 1.) flowers 1.35, Garcinia gummi-gutta ⁇ Garcinia cambogia) fruit 1.08, Red rice ( Oryza sativa L.) fermented seeds of Monascus Purpureus 0.902, Chinese rhubarb (Rheum palmatum L.) roots 0.54, Cola ( Cola acuminata Schott) fruit 0.270, Moringa (Moringa oleifera Lamk.) seeds 0.0675, Moringa (Moringa oleifera Lamk.) leaves 0.0675,
  • composition according to the present invention is a balanced supplement of nutrients which has shown to promote weight control in a surprising way, in the scope of a balanced diet, healthy lifestyle and regular physical exercise.
  • composition according to the present invention surprisingly is able to control the characterizing metabolic syndrome symptoms: in the experimental section which follows, the effect of the composition on the control of glycaemia, cholesterol, blood pressure and uric acid is shown by way of example in addition to the effect on weight.
  • a further object of the present invention is formed by said composition for use in the treatment of overweight, wherein said composition is administered to a subject from once to three times a day, preferably once a day, in an amount ranging between 20 and 80 ml, preferably between 25 and 60 ml, or between 30 and 45 ml, and even more preferably 37 ml.
  • said composition is formulated as a liquid composition.
  • it is formulated as a solid formulation, e.g. in powder or in tablets.
  • said composition is administered diluted in water in a ratio of 1 composition : 30 water, or 1:20, preferably 1:13.5.
  • Example 1 The results observed in a cohort of subjects to which a composition according to the present invention was administered, compared to a homogeneous untreated control group.
  • the subjects participating in the trial are selected and recruited under the supervision of a dietitian and a certified doctor from a group of healthy women, in accordance with inclusion criteria listed in the section which follows.
  • BMI Body mass index
  • the subject may be on effective contraceptive therapy (oral/non-oral ) 1.2 Development of the trial
  • Height is measured with the subject barefoot wearing underwear, using a height measuring rod.
  • Body weight is measured with the subject barefoot wearing underwear, using an electronic scale.
  • the abdomen, thigh and hip circumferences were measured using a tape measure (accuracy: 1 mm) .
  • Subcutaneous (SAT) and deep (DAT) adipose tissues are measured using an ultrasound-based imaging technique (Bodymetrix® BX2000, IntelaMetrix®) . The measurement is performed on the abdomen, thigh and hips .
  • Cholesterol, glycaemia and uric acid are measured using a EasyTouch® GCU glucose / cholesterol / uric acid multifunctional monitoring system (Bioptik Technology, Inc.) on capillary. The blood was obtained from a finger using a puncturer.
  • Systolic and diastolic blood pressure is measured using an automatic M3 OMRON IntelliSense blood pressure monitor (Omron Healthcare) .
  • Total body and extracellular water are measured with a BIA 101 device (Akern srl) .
  • the subjects are invited to express an opinion on the tested product by means of a self-assessment questionnaire.
  • p is the value of the parameter being analyzed
  • n is the number of subjects participating in the trial
  • p t is the value of the analyzed parameter after product application
  • po is the value of the analyzed parameter before product application
  • n is the number of subjects participating in the trial
  • p is the value of the parameter being analyzed
  • n is the number of subjects participating in the trial.
  • the data are subjected to two-way Student's t-test.
  • Table 1 The table below shows the data obtained for each subject participating in the trial. Data are expressed in kg. Figure 3 shows comparative data of up to 3 months of placebo and treatment.
  • composition according to the present invention composition according to the present invention.
  • Table 2a shows the data obtained for each subj ect participating in the trial. Data are expressed in cm.
  • Figure 4 shows comparative data of up to 3 months of placebo and treatment.
  • Table 2b below shows the data obtained for each subject participating in the trial. Data are expressed in cm.
  • Figure 5 shows comparative data of up to 3 months of placebo and treatment.
  • Table 3a shows the data obtained for each subj ect participating in the trial. Data are expressed in mm.
  • Figure 6 shows comparative data of up to 3 months of placebo and treatment.
  • Table 3b below shows the data obtained for each sub j ect participating in the trial. Data are expressed in mm.
  • Figure 7 shows comparative data of up to 3 months of placebo and treatment.
  • Table 3c shows the data obtained for each sub j ect participating in the trial. Data are expressed in mm. Figure 8 shows comparative data of up to 3 months of placebo and treatment. Table 3c
  • Table 3d below shows the data obtained for each subject participating in the trial. Data are expressed in mm. Figure 9 shows comparative data of up to 3 months of placebo and treatment. Table 3d
  • Table 3e shows the data obtained for each subject participating in the trial. Data are expressed in mm. Figure 10 shows comparative data of up to 3 months of placebo and treatment.
  • Table 3f below shows the data obtained for each subject participating in the trial. Data are expressed in mm. Figure 11 shows comparative data of up to 3 months of placebo and treatment.
  • Table 4a shows the data obtained for each subject participating in the trial. Data are expressed in mg/dl.
  • Figure 12 shows comparative data of up to 3 months of placebo and treatment.
  • Table 4b below shows the data obtained for each subject participating in the trial. Data are expressed in mg/dl.
  • Figure 13 shows comparative data of up to 3 months of placebo and treatment.
  • Table 4c shows the data obtained for each subject participating in the trial. Data are expressed in mg/dl. Figure 14 shows comparative data of up to 3 months of placebo and treatment. Table 4c
  • Table 5a shows the data obtained for each subj ect participating in the trial. Data are expressed in mmHg. Figure 15 shows comparative data of up to 3 months of placebo and treatment. Table 5a
  • Table 5b shows the data obtained for each subj ect participating in the trial. Data are expressed in mmHg. Figure 16 shows comparative data of up to 3 months of placebo and treatment. Table 5b
  • Table 6a shows the data obtained for each subject participating in the trial. Data are expressed in 1.
  • Figure 17 shows comparative data of up to 3 months of placebo and treatment.
  • Table 6b below shows the data obtained for each subject participating in the trial. Data are expressed in 1.
  • Figure 18 shows comparative data of up to 3 months of placebo and treatment.
  • Table 7a indicates the outputs emerged from the self-assessment questionnaires. Data are expressed as % of subjects who provided a specific answer.
  • Table 7b indicates the outputs emerged from the self-assessment questionnaires. Data are expressed as % of subjects who provided a specific answer.

Landscapes

  • Health & Medical Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Mycology (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Botany (AREA)
  • Microbiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Medical Informatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nutrition Science (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

La présente invention concerne un complément alimentaire qui est une composition qui comprend des substances naturelles et dont il a été démontré qu'il possède une activité surprenante en tant que coadjuvant dans des régimes amincissants. De manière inattendue, ladite composition s'est avérée efficace pour lutter contre les symptômes d'un syndrome métabolique caractéristique.
EP18830955.3A 2017-12-15 2018-12-12 Complément alimentaire Pending EP3723509A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IT201700145179 2017-12-15
PCT/IB2018/059905 WO2019116241A1 (fr) 2017-12-15 2018-12-12 Complément alimentaire

Publications (1)

Publication Number Publication Date
EP3723509A1 true EP3723509A1 (fr) 2020-10-21

Family

ID=61800603

Family Applications (1)

Application Number Title Priority Date Filing Date
EP18830955.3A Pending EP3723509A1 (fr) 2017-12-15 2018-12-12 Complément alimentaire

Country Status (3)

Country Link
EP (1) EP3723509A1 (fr)
MA (1) MA51187A (fr)
WO (1) WO2019116241A1 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102522975B1 (ko) * 2021-01-07 2023-04-19 주식회사 엠바이옴쎄라퓨틱스 신규한 모나스커스 퍼퓨리우스 sl1을 이용하여 제조된 모링가 발효물을 유효성분으로 함유한 항비만용 조성물

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1672988A4 (fr) * 2003-10-17 2008-02-20 Diet Formulations Ltd Complement nutritionnel d'amaigrissement
US20050276869A1 (en) * 2004-06-14 2005-12-15 Century Systems Appetite-suppressing, lipase-inhibiting herbal composition
US20060222682A1 (en) * 2005-03-18 2006-10-05 Andrews David A Nutraceutical Moringa composition
WO2015099616A1 (fr) * 2013-12-23 2015-07-02 Vitiva Proizvodnja In Storitve D.D. Mélange permettant de réduire la masse corporelle

Also Published As

Publication number Publication date
MA51187A (fr) 2020-10-21
WO2019116241A1 (fr) 2019-06-20

Similar Documents

Publication Publication Date Title
Singh et al. Prevalence and risk factors for prehypertension and hypertension in five Indian cities
Seo et al. Independent beneficial effects of aged garlic extract intake with regular exercise on cardiovascular risk in postmenopausal women
JP2007508329A (ja) 体重減少用サプリメント
US8119170B2 (en) Herbal compositions and methods for enhancing vital energy and athletic performance
CN104068080A (zh) 一种糖尿病人适用的饼干
CN104758920A (zh) 一种基于药食同源的痛风保健品
De Martin et al. The brown algae Fucus vesiculosus and Ascophyllum nodosum reduce metabolic syndrome risk factors: A clinical study
US20170239312A1 (en) Weight management systems and related methods
KR100572621B1 (ko) 비만 및 성인병 치료용 조성물
Benson et al. Improvement of joint range of motion (ROM) and reduction of chronic pain after consumption of an ergothioneine-containing nutritional supplement
JP2016088845A (ja) 抗疲労及び免疫増進用食品組成物
CN104000197A (zh) 一种缓解疲劳的保健品或药物组合物及其制备方法和用途
WO2019116241A1 (fr) Complément alimentaire
KR20140116988A (ko) 메틸설포닐메탄을 함유하는 류마티스 관절염 및 지질 대사 관련 질환의 예방 및 치료를 위한 약학적 조성물
CN101932332A (zh) 拉比西亚普米拉萃取物减低心血管疾病风险的应用
JP3452922B2 (ja) 平滑筋臓器の緊張を増加するため、および緊張を調節するための植物ベースの医薬
KR100880537B1 (ko) 칸탈로프 멜론추출물과 글리아딘 결합물을 유효성분으로 하는 기억, 집중력, 학습능력 개선제
US20210196764A1 (en) Method of preventing obesity using herb ferment
CN110935002A (zh) 具有降血压功效的组合物及其应用
Bagatela et al. The effects of a persimmon leaf oral supplement (Persimonal®) on cardiovascular health: a randomized, double-blinded, placebo-controlled study.
TW202515530A (zh) 對脂肪分解及／或體重減少之內用組成物、判斷有效性之方法以及植物萃取物之品質指標
CN113041269B (zh) 草本植物发酵物用于制备预防肥胖的组合物的用途
JP2018199624A (ja) 高血圧改善用組成物
Majeed et al. A new class of phytonutrients for body weight management
CN108936638A (zh) 一种降血脂保健食品及其制备方法

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: UNKNOWN

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20200609

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME